Having bioprocessing capacity is vital to being able to keep pace with demand for antibody therapies—and, in the future, cell therapies.
“The total global demand for monoclonal antibody products was approximately 8 metric tons in 2010, which we expect to grow to approximately 13.4 metric tons by 2016,” said Howard L. Levine, Ph.D., president and principal consultant at BioProcess Technology Consultants.
“Demand for the top five selling monoclonal antibody products will range from one to two metric tons each, helping to drive an approximately twofold increase in demand for cell culture capacity between now and 2016.
“Globally, the industry-wide utilization of cell culture manufacturing capacity will increase from around 50 percent to nearly 64 percent. However, with approximately 75 percent of the total global bioprocessing capacity controlled by ten companies, those companies without it may find access to it difficult in the future, resulting in the need for additional manufacturing capacity.”
Dr. Levine believes that the development of newer, more potent product types such as antibody drug conjugates (ADCs), which require less antibody concentration per dose, may lower the demand for mammalian cell culture capacity, as these products will require smaller facilities to produce.